


King Saud University  
College of Medicine  
2nd Year, 2nd Block

# GIT BLOCK



L2 - H2 blockers  
and proton pump  
inhibitors

# Mind map




# introduction

# Peptic ulcer

Definition	Pathophysiology	Etiology	Treatment
<p>▪ a localized lesion of the mucous membrane of the stomach (<b>gastric ulcer</b>) or duodenum (<b>duodenal ulcer</b>), typically extending through the muscularis mucosa.</p>	<p>is imbalance between aggressive factors (<b>acid &amp; pepsin</b>)</p> <p>And Defensive factors (e.g. <b>prostaglandins, mucus &amp; bicarbonate layer</b>)</p>	<ul style="list-style-type: none"> <li>• <b>H. pylori infection</b></li> <li>• Alcohol</li> <li>• Smoking</li> <li>• Caffeine</li> <li>• Genetic factors*<b>group O</b></li> <li>• Diet</li> <li>• Hypersecretory states "hypersecretion of HCL" (<b>Zollinger Ellison syndrome</b>)</li> <li>• Drugs (e.g.) <b>NSAIDs</b>.</li> </ul>	<ul style="list-style-type: none"> <li>• Eradication of H. pylori infections</li> <li>• Hyposecretory drugs.               <ol style="list-style-type: none"> <li>1. <b>Proton pump inhibitors</b></li> <li>2. <b>H<sub>2</sub> receptor blockers</b></li> <li>3. <b>Antimuscarinic drugs.</b></li> </ol> </li> <li>• Mucosal cytoprotective agents: <b>Prostaglandin analogues.</b></li> <li>• Neutralizing agents (antacids)</li> </ul>

## Gastric secretions

Types	Regulation	Gastric hyposecretory drugs
<ol style="list-style-type: none"> <li>1. <b>HCl</b> and intrinsic factor (Parietal cells).</li> <li>2. <b>Pepsinogens</b> (Chief cells).</li> <li>3. Mucus, bicarbonate (mucus-secreting cells)</li> </ol>	<p>Parietal cells secrete acid in response to:</p> <ol style="list-style-type: none"> <li>1. <b>Histamine (local hormone): H<sub>2</sub> receptors</b></li> <li>2. <b>Gastrin (hormone): CCK<sub>2</sub> receptors</b></li> <li>3. <b>Ach (neurotransmitter): M<sub>3</sub> receptors</b></li> <li>4. <b>Proton pump (H<sup>+</sup>/ K<sup>+</sup> ATPase)</b></li> </ol>	<ol style="list-style-type: none"> <li>1. <b>Proton pump inhibitors</b></li> <li>2. <b>H<sub>2</sub> receptor blockers</b></li> <li>3. <b>Antimuscarinic drugs</b></li> </ol> <p><b>Hyposecretory drugs</b> decrease gastric acid secretion  <b>➔ Promote healing &amp; relieve pain.</b></p>



Histamine H<sub>2</sub> receptor

Proton pump inhibitors

It happens inside the parietal cells + PP is the final step and after that the HCL will formed

# 1-Proton Pump Inhibitors (PPIs)

examples	Omeprazole	Lansoprazole	Pantoprazole	Raprazole
M.O.A	Acts by <b>irreversible inhibition of proton pump (H<sup>+</sup>/ K<sup>+</sup> ATPase)</b> that is responsible for final step in gastric acid secretion from the parietal cell. (Carbonic anhydrase involved in bicarbonate production )			
Pharmacodynamics	<p><b>They are the most potent inhibitors of acid secretion available today.</b></p> <p>Produce marked inhibition of basal &amp; meal stimulated-acid secretion (90-98%).</p> <p>Reduce pepsin activity.</p> <p>Promote mucosal healing &amp; decrease pain</p>			
Pharmacokinetics	<ul style="list-style-type: none"> <li>▪ Given orally as enteric coated capsules* <b>(unstable in acidic medium in stomach)</b>. *It means not dissolved unless reaching the intestine</li> <li>*Are pro-drugs (it get activated after administered). *Dose reduction is required in severe liver failure</li> <li>▪ rapidly absorbed from the intestine.</li> <li>▪ In the acidic medium of parietal cell canaliculi, they are activated.</li> <li>▪ Should not combined with H<sub>2</sub> blockers or antacids.*<b>because H2 blockers+antacid they decrease acidity and PPIs need an acid medium to get activated</b></li> <li>▪ At neutral pH, PPIs are inactivated. <span style="float: right;">Have long duration of action (&gt; 12 h-24 h)</span></li> <li>▪ Once daily dose is sufficient <span style="float: right;">Given 1 h before meal.</span></li> <li>▪ Bioavailability is reduced by food. <span style="float: right;">metabolized in the liver by Cyt-P450.</span></li> </ul>			

slide

doctor's note

important

explanation

## 2- Proton Pump Inhibitors (PPIs)

<b>Uses</b>	<ul style="list-style-type: none"><li>• <b>Eradication of <i>H. pylori</i></b> (combined with antimicrobial drugs).</li><li>• <b>Resistant severe peptic ulcer (4-8) weeks.</b></li><li>• Reflux esophagitis.</li><li>• Hypersecretory conditions as <b>Zollinger Ellison syndrome</b> and <b>gastrinoma*</b> (First choice)</li></ul>
<b>Adverse effects</b>	<ul style="list-style-type: none"><li>• Headache, diarrhea &amp; abdominal pain.</li><li>• Achlorhydria (gastric acid in stomach is decreased or absent)</li><li>• Hypergastrinaemia* (the presence of an excess of gastrin in the blood) *consequences to decreased HCL.</li><li>• Gastric mucosal hyperplasia</li><li>• Increased bacterial flora</li><li>• Increased risk of community-acquired respiratory infections &amp; nosocomial pneumonia</li></ul> <p>*Long term use:</p> <ol style="list-style-type: none"><li>1) <b>vitamin B12 deficiency.</b></li><li>2) <b>increased risk of hip joint fractures.</b></li></ol> <p>Long term use:</p>

### \*Zollinger Ellison syndrome (for your information)

Gastrin -secreting tumor of the pancreas.

Gastrin produces:

- Parietal cell hyperplasia (trophic factor).
- Excessive gastric acid production



## 2- H<sub>2</sub>- Histamine receptors blockers

Such as	- <b>Cimetidine</b> - <b>Ranitidine</b> - <b>Famotidine</b> - <b>Nizatidine</b>
MOA	They competitively and <b>reversibly block</b> H <sub>2</sub> receptors on the <u>parietal cells</u> .
Pharmacokinetics	<ul style="list-style-type: none"><li>❖ Good oral absorption, given I.V in ER</li><li>❖ Given before meals.</li><li>❖ <b>Famotidine is the most potent drug.</b></li><li>❖ Exposed to first pass metabolism (except <b>nizatidine</b> that has 100 % bioavailability).</li><li>❖ Duration of action (4-12 h).</li><li>❖ Metabolized by liver and excreted mainly in urine.</li></ul>
Pharmacological actions	<ul style="list-style-type: none"><li>✓ Reduce basal and food stimulated-acid secretion</li><li>✓ <b>better to be given <u>before night sleep</u></b> because Block 90% of nocturnal acid secretion (which depend largely on histamine) &amp; 60-70% of total 24 hr acid secretion.</li><li>✓ Promote mucosal healing &amp; decrease pain</li></ul>

## Uses

- ❖ GERD (heartburn/ dyspepsia).
- ❖ Acute ulcer healing in moderate duodenal ulcer (6-8 weeks) and benign gastric ulcer (8-12 weeks).
- ❖ Pre-anesthetic medication (to prevent aspiration pneumonitis).
- ❖ Prevention of bleeding from stress-related gastritis.
- ❖ Post-ulcer healing maintenance therapy (in absence of H.pylori).

## ADRs

- CNS effects: Headache – confusion, GIT disturbances (Nausea & Vomiting).
  - Elderly: hepatic dysfunction, renal dysfunction.
  - Bradycardia and hypotension (rapid I.V.)
- \* Special ADRs for Cimetidine
1. inhibits CYT-P45 leads to decrease metabolism of some drugs e.g.warfarin,phenytoin and benzodiazepines.
  2. drugs interaction.
  3. Dose reduction for elderly. \*centrally acting so high
  4. Endocrine effects:
    - A- Galactorrhea (Hyperprolactinemia )
    - B- **Antiandrogenic** actions (gynecomasteia –**impotence**) due to inhibition of dihydrotestosterone binding to androgen receptors.



### 3- Antacids:

These drugs are mainly **inorganic salts** they counteract the acidity  
e.g.:

NaHCO<sub>3</sub>: ADR  
Systemic  
alkalosis

Ca CO<sub>3</sub> : ADR  
milk alkali  
syndrome  
(hypercalcemia  
, renal failure)

Al (OH)<sub>3</sub> : ADR  
constipation;

Mg (OH)<sub>2</sub> :  
ADR Diarrhea

- 1) acts by direct chemical neutralization of HCL and may decrease pepsin activity.
- 2) used to: A) **relief pain of peptic ulcer**\*not for long time , B) **dyspepsia**.
- 3) All antacids ↓ **absorption of some drugs** e.g tetracycline, fluoroquinolones, iron.

## 4- Prostaglandin analogues (PGE1 )

Drug as	Misoprostol*not used any more because of it's short half life
MOA	1) ↓ HCL secretion 2) ↑ protective measures (↑ mucous/bicarbonate & gastric mucosal blood flow).
Pharmacokinetics	Orally, must be taken 3-4 times/day
Uses	NSAIDS-induced peptic ulcer.
ADRs	<ul style="list-style-type: none"><li>▪ Abdominal cramps; diarrhea</li><li>▪ Uterine contraction (dysmenorrhea or abortion);vaginal bleeding.</li></ul> *contraindicated in pregnancy.

# Summary

	Drugs	M.O.A	USES	Adverse effects
PPI	Omeprazole Lansoprazole Pantoprazole Raparazole	Acts by irreversible inhibition of proton pump (H <sup>+</sup> / K <sup>+</sup> ATPase) that is responsible for final step in gastric acid secretion from the parietal cell.	*Eradication of H. pylori + antimicrobial drugs *Resistant severe peptic ulcer ( 4-8 weeks). *Reflux esophagitis. *Hypersecretory conditions as Zollinger Ellison syndrome and gastrinoma (First choice).	*Headache, diarrhea & abdominal pain. <b>*Achlorhydria</b> <b>*Hypergastrinaemia.</b> <b>*Gastric mucosal hyperplasia.</b> <b>*Vitamin B<sub>12</sub> deficiency &amp; increased risk of hip fractures (Long term use )</b>
H2 Blockers	Cimetidine Ranitidine Famotidine Nizatidine	They competitively and reversibly block H <sub>2</sub> receptors on the parietal cells.	*GERD ((heartburn/ dyspepsia). *Acute ulcer healing in moderate cases *Pre-anesthetic (prevent aspiration pneumonitis). *Prevention of bleeding from stress-related gastritis. *Post-ulcer maintenance therapy.	*GIT disturbances & CNS effects *Bradycardia and hypotension *CYT-P450 inhibition + Endocrine effects (Only Cimetidine): Galactorrhea (Hyperprolactinemia ) Antiandrogenic actions (gynecomasteia –impotence) <b>*Precautions: Dose reduction of H<sub>2</sub> RAs in severe renal or hepatic failure and elderly.</b>
Antacids	NaHCO <sub>3</sub> Ca CO <sub>3</sub> Al (OH) <sub>3</sub> Mg (OH) <sub>2</sub>	acts by direct chemical neutralization of HCL and as a result may decrease pepsin activity	<b>used to relief pain of peptic ulcer &amp; for dyspepsia</b>	<b>*↓ absorption of some drugs</b> *Systemic alkalosis (NaHCO <sub>3</sub> ) *Diarrhea(Mg (OH) <sub>2</sub> ) *milk alkali syndrome (hypercalcemia, renal failure) (Ca CO <sub>3</sub> ) *constipation (Al (OH) <sub>3</sub> )
Prostaglandin analogues	Misoprostol	↓ HCL secretion. ↑ protective measures (↑ mucous/bicarbonate & gastric mucosal blood flow).	<b>Used for NSAIDS-induced peptic ulcer.</b>	*Abdominal cramps; diarrhea <b>*Uterine contraction (dysmenorrhoea or abortion);vaginal bleeding.</b>

# Quiz yourself

answers 1.B 2.C 3.A 4.B 5.A 6.B 7.C 8.B 9.A

1. Prostaglandin used in the treatment of peptic ulcer as:

- A. Hyposecretory agent
- B. Mucosal cytoprotective
- C. antioxidant

4. Which of the following drugs used to prevent aspiration pneumonitis ?

- A. Pantoprazole
- B. Ranitidine-
- C. Misoprostol

7. M.O.A of Antacids :

- A. inhibition of proton pump (H<sup>+</sup>/K<sup>+</sup> ATPase)
- B. block H<sub>2</sub>receptor
- C. Chemical neutralization of HCL and as a result decrease pepsin activity.

2. A peptic ulcer patient was prescribed with a drug, after long time he developed VB12 deficiency, the drug is ?

- A. Nizatidine
- B. Cimetidine
- C. Pantoprazole

5. A patient was using warfarin, and he developed peptic ulcer and started the treatment he suddenly developed warfarin toxicity, the drug is ?

- A. Cimetidine
- B. NSAIDs
- C. prostaglandin

8. A patient has an infection condition and was treated with NSAIDs, he suddenly developed peptic ulcer, the treatment is ?

- A. Cimetidine
- B. Misoprostol
- C. Rapaazole

3. The 1<sup>st</sup> drug of choice in the treatment of hypersecretory conditions as Zollinger Ellison syndrome is?

- A. Pantoprazole
- B. Ranitidine
- C. NaHCO<sub>3</sub>

6. 83 years old man developed peptic ulcer, which one of the following drugs is used with Precautions in this case ?

- A. NSAIDs
- B. Nizatidine
- C. Rapaazole

9. The most potent inhibitor of acid secretion nowadays is ?

- A. Omeprazole
- B. Famotidine
- C. Misoprostol



*Done by*

Raneem Alotaibi	Ahmed Aldakhil
Awatif alenazi	Omar Aldhas
Rawan Alotaibi	Faroq Abdulfattah
Noura Alrayes	

*It always seems  
impossible until it is done*

**BEST OF LUCK**



Pharma\_433@  
yahoo.com



@pharma\_433

